Eylea approved to treat wet age-related macular degeneration

Eylea (aflibercept)has been approved by the FDA to treat patients with wet (neovascular) age-related macular degeneration (AMD), a leading cause of vision loss and blindness in Americans ages 60 and older by gradually destroys a person’s sharp, central vision. It affects the macula, the part of the eye that allows people to see fine detail needed to do daily tasks such as reading and driving, as well as being able to read or recognize people’s faces.

Continue reading on Examiner.com Eylea approved to treat wet age-related macular degeneration – Hartford wellness | Examiner.com http://www.examiner.com/wellness-in-hartford/eylea-approved-to-treat-wet-age-related-macular-degeneration#ixzz1fi2V8QxC

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: